Risk factors and clinical outcomes associated with cytomegalovirus colitis in patients with acute severe ulcerative colitis

Inflammatory Bowel Diseases

Volumn 22, Issue 4, 2016, Pages 912-918

  Lee, Ho Su ^a   Park, Sang Hyoung ^b   Kim, Sung Han ^b   Kim, Jihun ^b   Choi, Jene ^b   Lee, Hyo Jeong ^a   Kim, Wan Soo ^b   Lee, Jeong Mi ^b   Kwak, Min Seob ^b   Hwang, Sung Wook ^b   Yang, Dong Hoon ^b   Kim, Kyung Jo ^b   Ye, Byong Duk ^b   Byeon, Jeong Sik ^b   Myung, Seung Jae ^b   Yoon, Yong Sik ^b   Yu, Chang Sik ^b   Kim, Jin Ho ^b   Yang, Suk Kyun ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

Author keywords

acute severe ulcerative colitis; colectomy; cytomegalovirus; outcome; treatment

Indexed keywords

CYCLOSPORIN; GANCICLOVIR; MERCAPTOPURINE; PREDNISOLONE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ACUTE SEVERE ULCERATIVE COLITIS; ADOLESCENT; ADULT; AGED; ARTICLE; COLON RESECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS COLITIS; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; ENDOSCOPIC BIOPSY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STEROID THERAPY; ULCERATIVE COLITIS; ACUTE DISEASE; COMPLICATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FOLLOW UP; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; SOUTH KOREA; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; COLITIS, ULCERATIVE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; RISK FACTORS; YOUNG ADULT;

EID: 84962287626     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000675     Document Type: Article

References (41)

1. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander?. Inflamm Bowel Dis. 2010;16:1620-1627.
2. Nakase H, Honzawa Y, Toyonaga T, et al. Diagnosis and treatment of ulcerative colitis with cytomegalovirus infection: importance of controlling mucosal inflammation to prevent cytomegalovirus reactivation. Intest Res. 2014;12:5-11.
3. Sager K, Alam S, Bond A, et al. Review article: cytomegalovirus and inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41:725-733.
4. Papadakis KA, Tung JK, Binder SW, et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96:2137-2142.
5. Kishore J, Ghoshal U, Ghoshal UC, et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol. 2004;53:1155-1160.
6. Domenech E, Vega R, Ojanguren I, et al. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis. 2008;14:1373-1379.
7. Maher MM, Nassar MI. Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease. Dig Dis Sci. 2009;54:2456-2462.
8. Gauss A, Rosenstiel S, Schnitzler P, et al. Intestinal cytomegalovirus infection in patients hospitalized for exacerbation of inflammatory bowel disease: a 10-year tertiary referral center experience. Eur J Gastroenterol Hepatol. 2015;27:712-720.
9. Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a metaregression. Clin Gastroenterol Hepatol. 2007;5:103-110.
10. Bitton A, Buie D, Enns R, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179-194.
11. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030.
12. Yi F, Zhao J, Luckheeram RV, et al. The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China. Virol J. 2013;10:43.
13. Cottone M, Pietrosi G, Martorana G, et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn?s colitis. Am J Gastroenterol. 2001;96:773-775.
14. Roblin X, Pillet S, Oussalah A, et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2011;106:2001-2008.
15. Dimitroulia E, Spanakis N, Konstantinidou AE, et al. Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:879-884.
16. McCurdy JD, Jones A, Enders FT, et al. A model for identifying cytomegalovirus in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13:131-137.
17. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J. 1954;2:375-378.
18. Lee HS, Yang SK, Soh JS, et al. Short-And long-Term outcomes of acute severe ulcerative colitis in korea: the 1999-2005 cohort. Inflamm Bowel Dis. 2015;21:1825-1831.
19. Park SH, Yang SK, Park SK, et al. Long-Term prognosis of crohn?s disease and its temporal change between 1981 and 2012: a hospitalbased cohort study from Korea. Inflamm Bowel Dis. 2014;20:488-494.
20. Lee HS, Park SH, Yang SK, et al. Long-Term prognosis of ulcerative colitis and its temporal change between 1977 and 2013: a hospitalbased cohort study from Korea. J Crohns Colitis. 2015;9:147-155.
21. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn?s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99:878-883.
22. Kim JW, Boo SJ, Ye BD, et al. Clinical utility of cytomegalovirus antigenemia assay and blood cytomegalovirus DNA PCR for cytomegaloviral colitis patients with moderate to severe ulcerative colitis. J Crohns Colitis. 2014;8:693-701.
23. Travis SP, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145:987-995.
24. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905-910.
25. Jang EY, Park SY, Lee EJ, et al. Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. Clin Infect Dis. 2009;48:e121-E124.
26. Park SH, Yang SK, Hong SM, et al. Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis. Dig Dis Sci. 2013;58:3592-3599.
27. Maconi G, Colombo E, Zerbi P, et al. Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. Dig Liver Dis. 2005;37:418-423.
28. Kim YS, Kim YH, Kim JS, et al. The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. J Clin Gastroenterol. 2012;46:51-56.
29. Ayre K, Warren BF, Jeffery K, et al. The role of CMV in steroid-resistant ulcerative colitis: a systematic review. J Crohns Colitis. 2009;3:141-148.
30. Chun J, Lee C, Kwon JE, et al. Usefulness of the cytomegalovirus antigenemia assay in patients with ulcerative colitis. Intest Res. 2015;13:50-59.
31. Nguyen M, Bradford K, Zhang X, et al. Severity of cytomegalovirus infection on pathology specimens is associated with colectomy rates and response to antiviral therapy in inflammatory bowel fisease patients. Gastroenterology. 2010;138:S-144-S-145.
32. Hodinka RL. Human cytomegalovirus. In: Manual of Clinical Microbiology. 11th ed. Washington, DC: American Society of Microbiology; 2015: 1718-1737.
33. Forbes BA, Bonville CA, Dock NL. The effects of a promoter of cell differentiation and selected hormones on human cytomegalovirus infection using an in vitro cell system. J Infect Dis. 1990;162:39-45.
34. Gratama JW, Brooimans RA, van der Holt B, et al. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytometry B Clin Cytom. 2008;74:211-220.
35. Widmann T, Sester U, Gartner BC, et al. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS One. 2008;3:e3634.
36. Wada Y, Matsui T, Matake H, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum. 2003;46:S59-S65.
37. Iida T, Ikeya K, Watanabe F, et al. Looking for endoscopic features of cytomegalovirus colitis: a study of 187 patients with active ulcerative colitis, positive and negative for cytomegalovirus. Inflamm Bowel Dis. 2013;19:1156-1163.
38. Omiya M, Matsushita M, Tanaka T, et al. The absence of large ulcer predicts latent cytomegalovirus infection in ulcerative colitis with positive mucosal viral assay. Intern Med. 2010;49:2277-2282.
39. Park M, Lee YH, Lee SH, et al. Cytomegalovirus infection in seropositive unrelated cord blood recipients: a study of 349 Korean patients. Ann Hematol. 2015;94:481-489.
40. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis. 2010;50:1439-1447.
41. Kim YS, Kim YH, Kim JS, et al. Long-Term outcomes of cytomegalovirus reactivation in patients with moderate to severe ulcerative colitis: a multicenter study. Gut Liver. 2014;8:643-647.